Immunicon (IMMC) Awarded Research Services Agreement with Bristol-Myers
More News related to BMY
- KineMed Broadens Collaboration with Bristol-Myers Squibb
- Tasigna Front Line Data Convincing But Not Enough to Displace Gleevec
- Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c; Guides
- Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009
- European Commission Approves ORENCIA(R) (abatacept) in Combination with Methotrexate for Children with Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (pJIA)
More News related to IMMC
- Immunicon (IMMC) CFO Resigns
- Immunicon (IMMC) CFO To Resign
- Immunicon (IMMC) Appoints Dr. J. William Freytaga as Chairman
- Immunicon (IMMC) Awarded Research Services Agreement with Bristol-Myers
- Immunicon (IMMC) Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount System at AARC
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Immunicon Corporation (NASDAQ: IMMC) entered into a Research Services Agreement with Bristol-Myers Squibb (NYSE: BMY) involving protein and molecular targets associated with circulating tumor cells.
Related Categories
Corporate NewsStocks Mentioned
+0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
